Heartburn News and Research

RSS

Heartburn, also know as acid reflux, is a painful and burning sensation in the esophagus, just behind the breastbone usually associated with regurgitation of gastric acid (gastric reflux).

FDA approves Santarus’ NDA for immediate-release prescription tablet product

Santarus, Inc., a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s New Drug Application (NDA) for immediate-release omeprazole/sodium bicarbonate/ magnesium hydroxide tablets in 40 mg and 20 mg dosage strengths of omeprazole.

5 Dec 2009

FDA approves manufacture of Amneal Pharmaceuticals' Nizatidine Oral Solution

Amneal Pharmaceuticals is pleased to announce that it has received U.S. FDA approval to manufacture Nizatidine Oral Solution in the 15 mg/mL strength effective November 18, 2009. It is an AA-rated, therapeutically equivalent alternative to Axid® Oral Solution (a licensed trademark of Braintree Labs). Nizatidine Oral Solution is the first available generic in oral solution form and marks Amneal’s fourth liquid approval.

3 Dec 2009

FDA approves Schering-Plough's New Drug Application for ZEGERID OTC capsules

Santarus, Inc., a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Schering-Plough HealthCare Products, Inc.’s, New Drug Application (NDA) for ZEGERID OTC™ Capsules (omeprazole/sodium bicarbonate) with a dosage strength of 20 mg of omeprazole for over-the-counter (OTC) treatment of frequent heartburn.

2 Dec 2009

ZEGERID OTC, a proton pump inhibitor receives FDA approval

Merck & Co., Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ZEGERID OTC(TM) (omeprazole 20 mg/sodium bicarbonate 1100 mg capsules), for over-the-counter treatment of frequent heartburn.

2 Dec 2009

EGS announces closure of $21.5 million Series E financing

EndoGastric Solutions (EGS) today announced the closing of a $21.5 Million Series E financing. The funding will be used to support an expanding commercial presence for the company’s market-leading Natural Orifice Surgery (NOS) platform, which includes the EsophyX and StomaphyX surgical devices.

25 Nov 2009

GERD is an immune-mediated injury and not the result of acid burn, says new study

Contrary to current thinking, a condition called gastroesophageal reflux disease (GERD) might not develop as a direct result of acidic digestive juices burning the esophagus, UT Southwestern Medical Center researchers have found in an animal study.

20 Nov 2009

VerifyNow System, a rapid platelet function assessment platform, evaluated at AHA's Scientific Sessions

Accumetrics, Inc., developer of the VerifyNow System, the first point-of-care method for measuring platelet reactivity, announces that its market-leading VerifyNow P2Y12 Test was one of multiple methods evaluated in the POPular study, which was presented during a Late Breaking Clinical Trials session at the American Heart Association's annual Scientific Sessions.

20 Nov 2009

Drug interaction between clopidogrel and omeprazole: New safety information

Today the FDA notified healthcare professionals of new safety information concerning a drug interaction between clopidogrel, an anti-clotting medication, and omeprazole, a proton pump inhibitor (PPI) used to reduce stomach acid.

18 Nov 2009

Frequent heartburn is painful and impacts the quality of life: Study

While most adults have likely experienced the uncomfortable symptoms of heartburn at least once, for the 50 million American adults who suffer from frequent heartburn two or more days per week, the condition is not only painful, it can also impact their quality of life.

12 Nov 2009

High prevalence of nocturnal teeth grinding in patients with OSA

There is a high prevalence of nocturnal teeth grinding, or bruxism, in patients with obstructive sleep apnea (OSA), particularly in Caucasians. New research presented at CHEST 2009, the 75th annual international scientific assembly of the American College of Chest Physicians (ACCP), found that nearly 1 in 4 patients with OSA suffers from nighttime teeth grinding; this seems to be especially more prevalent in men and in Caucasians compared with other ethnic groups.

3 Nov 2009

Genetic susceptibility study for Barrett's esophagus and esophageal adenocarcinoma awarded $7.9M grant

Thomas Vaughan, M.D., head of the Epidemiology Program in the Public Health Sciences Division of Fred Hutchinson Cancer Research Center, has received a three-year, $7.9 million grant from the National Cancer Institute to study genetic susceptibility for Barrett's esophagus and esophageal adenocarcinoma, a rapidly fatal cancer whose incidence has increased more than 500 percent in the past 30 years, faster than any other cancer in the United States.

31 Oct 2009

GI Solutions to conduct new incision-free procedure for GERD patients

Chicago woman will be among the first in the country to undergo a new incision-less, endoscopic procedure that could get rid of Gastrointestinal Esophageal Reflux Disease (GERD) forever.

27 Oct 2009

New data on KAPIDEX for nighttime heartburn in adults with non-erosive GERD presented at the 2009 ACG

New data being presented at the American College of Gastroenterology (ACG) 2009 Annual Scientific Meeting in San Diego showed that treatment with KAPIDEX(TM) (dexlansoprazole) delayed release capsules over a four-week period resulted in a statistically significant greater percentage of nights without heartburn in subjects with non-erosive gastroesophageal reflux disease (GERD), compared to placebo (p<0.001).

27 Oct 2009

BMC surgeons use new EsophyX TIF for treatment of acid reflux or GERD

Boston Medical Center (BMC) surgeons are now offering patients an incisionless alternative to laparoscopic and traditional surgery for treatment of acid reflux or GERD.

27 Oct 2009

ZANTAC(R) Chili Challenge attracts thousands of Canadian participants

There are few dishes that bring out as much pride and passion from Canadians as chili. With football season and plunging temperatures in full swing, there is no better time for chili enthusiasts to get back into the kitchen, perfect their chili recipes and put them to the ultimate test in the second annual ZANTAC(R) Chili Challenge.

26 Oct 2009

Workers with MetS can cost employers up to $5,867 in health care annually: Study

Someone healthy enough to work could still cost an employer more than $4,000 annually in unnecessary health care costs.

23 Oct 2009

XenoPort commences Phase 2b arbaclofen placarbil clinical trial for treating gastroesophageal reflux disease

XenoPort, Inc. announced today that it has initiated a Phase 2b clinical trial of arbaclofen placarbil (AP), also known as XP19986, in patients with gastroesophageal reflux disease (GERD) who remain symptomatic despite treatment with a proton pump inhibitor (PPI). The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of AP as adjunctive therapy to PPIs.

19 Oct 2009

Benefits of health overhaul won't be immediate

Mechanisms to make health insurance more affordable for families and low- and middle-income households won't start until 2013 if health care reform passes.

12 Oct 2009

Researchers reveal that H2 Blocker drugs pose no significant risks for the fetus

H2 Blocker drugs, such as Famotidine, Cimetidine and Ranitidine, approved in the U.S. for acid reflux (heartburn), pose no significant risks for the fetus according to a large collaborative cohort study by researchers at Ben-Gurion University of the Negev.

8 Oct 2009

Global retail market for probiotic foods and beverages shows 13 percent increase over 2007

Once relegated primarily to the domain of yogurt and high-fiber fare, the market for food and beverage products fortified with probiotics and prebiotics has taken off as digestive health emerged as one of the hottest topics in the food and beverage arena.

5 Oct 2009

Heartburn News and Research

Further Reading

FDA approves Santarus’ NDA for immediate-release prescription tablet product

FDA approves manufacture of Amneal Pharmaceuticals' Nizatidine Oral Solution

FDA approves Schering-Plough's New Drug Application for ZEGERID OTC capsules

ZEGERID OTC, a proton pump inhibitor receives FDA approval

EGS announces closure of $21.5 million Series E financing

GERD is an immune-mediated injury and not the result of acid burn, says new study

VerifyNow System, a rapid platelet function assessment platform, evaluated at AHA's Scientific Sessions

Drug interaction between clopidogrel and omeprazole: New safety information

Frequent heartburn is painful and impacts the quality of life: Study

High prevalence of nocturnal teeth grinding in patients with OSA

Genetic susceptibility study for Barrett's esophagus and esophageal adenocarcinoma awarded $7.9M grant

GI Solutions to conduct new incision-free procedure for GERD patients

New data on KAPIDEX for nighttime heartburn in adults with non-erosive GERD presented at the 2009 ACG

BMC surgeons use new EsophyX TIF for treatment of acid reflux or GERD

ZANTAC(R) Chili Challenge attracts thousands of Canadian participants

Workers with MetS can cost employers up to $5,867 in health care annually: Study

XenoPort commences Phase 2b arbaclofen placarbil clinical trial for treating gastroesophageal reflux disease

Benefits of health overhaul won't be immediate

Researchers reveal that H2 Blocker drugs pose no significant risks for the fetus

Global retail market for probiotic foods and beverages shows 13 percent increase over 2007

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News